ideology-health
  • Our Solutions
  • About Us
  • ideology-health
    Privacy Policy
    Terms of Service
    Inc. 5000

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2026 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.

    Dr. Martin Dietrich discusses the efficacy of trastuzumab deruxtecan (T-Dxd) in HER2+ colorectal cancer  (Video 1/3)
    Sign up to watch this video

    Free access to all Sound Bites content

    Dr. Martin Dietrich discusses the efficacy of trastuzumab deruxtecan (T-Dxd) in HER2+ colorectal cancer (Video 1/3)

    Published May 5, 2026


    M

    Martin Dietrich

    Medical Professional


    T-Dxd in HER2+ CRC


    More in this series: T-Dxd in CRC 2026
    Dr. Martin Dietrich reviews the evidence trastuzumab deruxtecan (T-Dxd) in gastric cancer (Video 2/3)

    Dr. Martin Dietrich reviews the evidence trastuzumab deruxtecan (T-Dxd) in gastric cancer (Video 2/3)

    T-Dxd in Gastric

    Martin Dietrich
    GI Cancers
    Dr. Martin Dietrich describes the safety of trastuzumab deruxtecan and practical strategies for managing adverse effects (Video 3/3)

    Dr. Martin Dietrich describes the safety of trastuzumab deruxtecan and practical strategies for managing adverse effects (Video 3/3)

    Safety of T-Dxd

    Martin Dietrich
    GI Cancers
    Related Videos
    Dr. Rahul Banerjee reviews the safety profile of iberdomide and strategies for adverse event management (Video 3/3)

    Dr. Rahul Banerjee reviews the safety profile of iberdomide and strategies for adverse event management (Video 3/3)

    Rahul Banerjee, MD
    Dr. Wade Iams describes an MDT approach to optimally care for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 3/3)

    Dr. Wade Iams describes an MDT approach to optimally care for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 3/3)

    Wade Iams, MD
    Dr. Rahul Banerjee highlights key findings with iberdomide, daratumumab, and dexamethasone in RRMM. (Video 2/3)

    Dr. Rahul Banerjee highlights key findings with iberdomide, daratumumab, and dexamethasone in RRMM. (Video 2/3)

    Rahul Banerjee, MD
    Dr. Gabriela Hobbs discusses event-free survival outcomes with ropeginterferon in polycythemia vera (Video 3/3)

    Dr. Gabriela Hobbs discusses event-free survival outcomes with ropeginterferon in polycythemia vera (Video 3/3)

    Gabriela Hobbs, MD
    Dr. Eytan Stein explores how emerging clinical data and real-world experience are shaping the treatment landscape in AML (Video 3/3)

    Dr. Eytan Stein explores how emerging clinical data and real-world experience are shaping the treatment landscape in AML (Video 3/3)

    Eytan Stein, MD
    Dr. Wade Iams reviews the efficacy of dose interruption/reduction strategies for patients with EGFRm mNSCLC on 1L amivantamab + lazertinib (Video 2/3)

    Dr. Wade Iams reviews the efficacy of dose interruption/reduction strategies for patients with EGFRm mNSCLC on 1L amivantamab + lazertinib (Video 2/3)

    Wade Iams, MD